# Phase 1 dermatitis trials recruiting: 28 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials in phase 1 for dermatitis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 dermatitis trials: 28 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/dermatitis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 28
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07941388 | A Phase I Study of INT-1868 Tablets in Healthy Adult Participants (INT-1868-I101) | Innatus Therapeutics (Shanghai) Co., Ltd. | Phase 1 | Not yet recruiting | Atopic Dermatitis (AD) | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941388) |
| November 6, 2026 | NCT07920809 | A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis | Haisco Pharmaceutical Group Co., Ltd. | Phase 1 | Not yet recruiting | Dermatitis Atopic | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920809) |
| November 6, 2026 | NCT07920783 | A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants | Gan & Lee Pharmaceuticals. | Phase 1 | Not yet recruiting | Atopic Dermatitis | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920783) |
| October 29, 2026 | NCT07904689 | A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis | North Immunology Inc. | Phase 1 | Not yet recruiting | Atopic Dermatitis (AD) | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904689) |
| September 2, 2026 | NCT07800104 | Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis | QuantX Biosciences US Inc. | Phase 1 | Recruiting | Atopic Dermatitis | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800104) |
| August 5, 2026 | NCT07746817 | A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis | Bionyra Pharma | Phase 1 | Recruiting | Atopic Dermatitis, Healthy Participants | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746817) |
| July 13, 2026 | NCT07698756 | A Clinical Study of HRS-8797 in Healthy Participants | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Atopic Dermatitis | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698756) |
| May 22, 2026 | NCT07604324 | A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to... | Novartis Pharmaceuticals | Phase 1 | Recruiting | Dermatitis, Atopic | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604324) |
| April 24, 2026 | NCT07549984 | A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Not yet recruiting | Atopic Dermatitis | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549984) |
| April 24, 2026 | NCT07549750 | A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants | Helixon Biotechnology (Suzhou) Co., Ltd | Phase 1 | Not yet recruiting | Atopic Dermatitis | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549750) |
| April 14, 2026 | NCT07527923 | First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis | Regeneron Pharmaceuticals | Phase 1 | Recruiting | Healthy Volunteer, Atopic Dermatitis | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527923) |
| March 23, 2026 | NCT07488065 | A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 1 | Recruiting | Atopic Dermatitis | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488065) |
| March 6, 2026 | NCT07455578 | Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease | Seismic Therapeutic AU Pty Ltd | Phase 1 | Recruiting | Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO), Cutaneous Lupus... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455578) |
| March 6, 2026 | NCT07453602 | Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 | Arcutis Biotherapeutics, Inc. | Phase 1 | Recruiting | Atopic Dermatitis (AD), Eczema | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07453602) |
| February 17, 2026 | NCT07414602 | A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Dermatitis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07414602) |
| February 11, 2026 | NCT07404033 | ZYG24002 Lotion to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Adult Patients With Mild to Moderate... | Sinomune Pharmaceutical Co., Ltd | Phase 1 | Recruiting | Seborrheic Dermatitis | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07404033) |
| January 22, 2026 | NCT07358156 | A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in... | Chong Kun Dang Pharmaceutical | Phase 1 | Recruiting | Atopic Dermatitis | 519 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358156) |
| December 4, 2025 | NCT07262983 | Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Recruiting | Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome, HIES, Lupus, Atopic Dermatitis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262983) |
| November 20, 2025 | NCT07239947 | A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) | Bambusa Therapeutics | Phase 1 | Recruiting | Atopic Dermatitis | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07239947) |
| November 19, 2025 | NCT07235384 | A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to... | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Recruiting | Atopic Dermatitis (AD) | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07235384) |
| June 27, 2025 | NCT07042113 | A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 | Not yet recruiting | Atopic Dermatitis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07042113) |
| June 11, 2025 | NCT07015762 | A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis | The First Affiliated Hospital of Soochow University | Phase 1 | Recruiting | Atopic Dermatitis | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07015762) |
| May 21, 2025 | NCT06982352 | Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis | LAPIX Therapeutics Inc. | Phase 1 | Recruiting | Atopic Dermatitis (AD), Psoriasis (PsO) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06982352) |
| April 27, 2025 | NCT06946641 | A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic... | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 | Recruiting | Atopic Dermatitis, Hidradenitis Suppurativa (HS), Rheumatoid Arthritis (RA) | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06946641) |
| February 5, 2025 | NCT06808477 | A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) | Bambusa Therapeutics | Phase 1 | Recruiting | Atopic Dermatitis | 237 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06808477) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Bambusa Therapeutics | 2 |
| [Zai Lab (Shanghai) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/zai-lab-shanghai-co-ltd) | 1 |
| [Haisco Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/haisco-pharmaceutical-group-co-ltd) | 1 |
| Sinomune Pharmaceutical Co., Ltd | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 1 |
| [Gan & Lee Pharmaceuticals.](https://specstream.ai/data/clinical-trials/company/gan-and-lee-pharmaceuticals) | 1 |
| Brexogen Inc. | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| LAPIX Therapeutics Inc. | 1 |
| Helixon Biotechnology (Suzhou) Co., Ltd | 1 |
| [Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-kelun-biotech-biopharmaceutical-co-ltd) | 1 |
| [Arcutis Biotherapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/arcutis-biotherapeutics-inc) | 1 |
| Shanghai Qilu Pharmaceutical Research and Development Center LTD | 1 |
| [Chong Kun Dang Pharmaceutical](https://specstream.ai/data/clinical-trials/company/chong-kun-dang-pharmaceutical) | 1 |
| [Chengdu Suncadia Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chengdu-suncadia-medicine-co-ltd) | 1 |
| Seismic Therapeutic AU Pty Ltd | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
| Innatus Therapeutics (Shanghai) Co., Ltd. | 1 |
| QuantX Biosciences US Inc. | 1 |
| [Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sunshine-guojian-pharmaceutical-shanghai-co-ltd) | 1 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 1 |
| Bionyra Pharma | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 13 |
| United States | 8 |
| Australia | 6 |
| New Zealand | 2 |
| Poland | 2 |
| Japan | 1 |
| Belgium | 1 |
| Jordan | 1 |
| Germany | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Dominican restaurants in the United States](https://specstream.ai/data/businesses/dominican-restaurants/united-states)
- [Lawn care companies in the United States](https://specstream.ai/data/businesses/lawn-care-companies/united-states)
- [Septic services in the United States](https://specstream.ai/data/businesses/septic-services/united-states)
- [B2B oil and gas exploration and development companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-exploration-and-development-companies/united-states)
- [Excavation contractors in the United States](https://specstream.ai/data/businesses/excavation-contractors/united-states)
- [Mobility equipment companies in the United States](https://specstream.ai/data/businesses/mobility-equipment-companies/united-states)
